Sanofi Aventis Pakistan Limited Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2012; Provides Earnings Guidance for the Remaining Quarters of 2012
April 30, 2012 at 10:13 pm
Share
Sanofi Aventis Pakistan Limited reported unaudited earnings results for the first quarter ended March 31, 2012. For the quarter, the company reported net profit of PKR 10,155,000 or PKR 1.05 per basic share on net sales of PKR 1,920,962,000 compared to net loss of PKR 7,200,000 or PKR 0.75 per basic share on net sales of PKR 1,900,934,000 a year ago. Operating profit was PKR 81,837,000 compared to PKR 70,664,000 a year ago. Profit before taxation was PKR 51,913,000 compared to PKR 46,188,000 a year ago. Total comprehensive income was PKR 10,155,000 compared to loss of PKR 7,200,000 a year ago. Net cash generated from operating activities was PKR 94,069,000 compared to PKR 269,386,000 a year ago. Capital expenditures were PKR 26,280,000 compared to PKR 6,739,000 a year ago. The
sales growth, despite the challenging business environment, is the result of the company's strategy to become "A diversified health-care company with patient centric approach". Operating income for the period includes gain on sales of scrap and license fee from related party amounting to PKR 2,610,000 and PKR 2,300,000 respectively.
Barring unforeseen events, the company expects the sales growth in the remaining quarters of 2012 to be in line with the industry trend. However, due to an adverse impact of Pakistan Rupee depreciation and inflation, overall profitability is an area of concern for the Pharmaceutical industry.
Hoechst Pakistan Limited is a pharmaceutical company. The Company is engaged in the manufacturing, selling and trading of pharmaceutical and related products. The Company offers solutions for various therapeutic areas, such as antibiotics, cardiology, diabetes, pain and allergy and others. Its patient programs address unmet needs around access and education across Pakistan to support people with diabetes. It provides and delivers therapeutic solutions for cardiovascular diseases (CVDs) and works with healthcare professionals to impart awareness and knowledge to patients who are at risk of developing heart diseases. Its products include ampoules, vials, tablets and capsules, and oral liquids. Its brands include Flagyl, Clexane, No-Spa, Lantus, Amaryl, Claforan, Haemaccel, Enterogermina, Plavix and Selsun Blue. Selsun Blue helps treat and prevent dandruff symptoms by targeting dandruff from the source and thus soothes irritated scalp, fights itch and controls visible flakes.
Sanofi Aventis Pakistan Limited Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2012; Provides Earnings Guidance for the Remaining Quarters of 2012